Comments

Gain Therapeutics Stock Price, Quotes and Forecasts

Q: What sector and industry does Gain Therapeutics (GANX) operate in?

Gain Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

GANXNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Gain Therapeutics (GANX) Forecast

News Earnings Gain Therapeutics (GANX) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Gain Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:GANX | Benzinga

Explore Gain Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for GANX.

Open	$2.14
Close	-
Volume / Avg.	74.66K / 236.07K
Day Range	$2.14 - $2.26
52 Wk Range	0.89 - 4.63
Market Cap	$59.15M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	54
Short Interest	1.38%
Days to Cover	1.22

Recent News

Small-Cap Gain Therapeutics Stock Falls On Phase 1 Data From Its Lead Asset For Parkinson's Disease

Gain Therapeutics reported positive Phase 1 results for GT-02287, showing safety and tolerability across all age groups. The company plans a Parkinson's disease trial by Q4 2024.

Vandana Singh

S&P 500 Edges Lower; RH Shares Plunge After Q1 Results

Avi Kapoor

Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Oct 24

Nov 24

Dec 24

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.6

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$2.14
Close	-
Volume / Avg.	74.66K / 236.07K
Day Range	$2.14 - $2.26
52 Wk Range	0.89 - 4.63
Market Cap	$59.15M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	54
Short Interest	1.38%
Days to Cover	1.22

About Gain Therapeutics Inc

Sector

Health Care

Industry

Biotechnology

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to tre...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Gain Therapeutics (GANX) stock?

You can purchase shares of Gain Therapeutics (NASDAQ:GANX) through any online brokerage.

View our list of the best stock brokerages

Who are Gain Therapeutics (GANX) competitors?

Other companies in Gain Therapeutics’s space includes: Outlook Therapeutics (NASDAQ:OTLK), CytomX Therapeutics (NASDAQ:CTMX), Connect Biopharma Hldgs (NASDAQ:CNTB), Burning Rock Biotech (NASDAQ:BNR) and Immuneering (NASDAQ:IMRX).

What is the forecast, or price target, for Gain Therapeutics (GANX) stock?

Gain Therapeutics has a consensus price target of $8.33.

What is the current price for Gain Therapeutics (GANX)?

The stock price for Gain Therapeutics (NASDAQ: GANX) is $2.23 last updated March 17, 2025 at 10:38 AM EDT.

Does Gain Therapeutics (GANX) pay a dividend?

There are no upcoming dividends for Gain Therapeutics.

When is Gain Therapeutics (NASDAQ:GANX) reporting earnings?

Gain Therapeutics’s Q1 earnings are confirmed for Tuesday, May 13, 2025.

Is Gain Therapeutics (GANX) going to split?

There is no upcoming split for Gain Therapeutics.

What sector and industry does Gain Therapeutics (GANX) operate in?

Gain Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.